Veterinary Anti-infectives Market Set for Strong Expansion Reaching USD 13.27 Billion by 2032

The global Veterinary Anti-infectives Market recorded a valuation of USD 8.32 billion in 2024 and is projected to reach USD 13.27 billion by 2032, advancing at a 6.10% CAGR from 2025 to 2032. With increasing disease outbreaks among livestock and companion animals, the market is witnessing substantial demand for antimicrobials, antivirals, and specialized treatment solutions. The rising consumption of meat and dairy products, combined with the expansion of commercial farming operations, further accelerates product adoption across high-demand regions.

Growing pet ownership, particularly in Asia-Pacific, has significantly boosted spending on preventive and therapeutic veterinary care. At the same time, rapid advancements in diagnostics such as PCR and ELISA have enabled early detection of infectious diseases, supporting the use of targeted, fast-acting anti-infectives. These developments have driven pharmaceutical companies to innovate new formulations with higher efficacy and improved delivery methods.

Get free Sample Report@ https://www.snsinsider.com/sample-request/7803

The U.S. remains one of the most influential markets, valued at USD 2.29 billion in 2024 and expected to reach USD 3.54 billion by 2032 at a CAGR of 5.70%. This growth is supported by advanced veterinary infrastructure, the presence of top market players, and high adoption of prescription-based treatments. Regulatory agencies in North America maintain stringent requirements for drug approval, ensuring product safety and effectiveness while influencing R&D investments and market entry strategies.

Livestock animals accounted for 68.5% of the market share in 2024 as demand for safe and efficient anti-infectives continues to rise in commercial farming. Companion animals represent the fastest-growing segment due to increased pet humanization and shifting consumer focus toward premium healthcare solutions. Pet owners are prioritizing routine health checkups, advanced diagnostics, and preventive treatments, resulting in rising consumption of prescription and OTC products.

Antimicrobials dominated product type with 52.14% share in 2024, supported by their widespread use in managing bacterial infections in cattle, swine, poultry, and pets. However, antivirals are projected to grow at the fastest rate over the forecast period as viral outbreaks become more frequent globally. Enhanced diagnostic tools have made it easier to identify viral infections early, fueling the demand for new antiviral formulations.

Oral administration held 72.26% of the market in 2024 thanks to ease of dosage, cost efficiency, and suitability for mass treatment programs in livestock. Meanwhile, topical and intramammary routes are gaining traction due to advances in targeted delivery platforms that minimize systemic exposure and improve recovery outcomes. OTC products maintained a dominant 73.10% share due to accessibility in emerging regions, while prescription products grow steadily under antimicrobial stewardship regulations requiring veterinary supervision.

Retail pharmacies accounted for 76% of sales in 2024, driven by wide availability and consumer trust. E-commerce is the fastest-growing channel as digital adoption accelerates across veterinary healthcare. Online platforms offer convenience, competitive pricing, and strong distribution networks, making them especially popular in Asia-Pacific and Europe.

North America represented the largest regional market with 36.12% share in 2024, supported by mature veterinary healthcare systems and proactive disease management programs. Asia-Pacific is the fastest-growing region with a 6.67% CAGR, driven by expanding livestock sectors, rising meat consumption, and increasing pet ownership across China, India, and Southeast Asia. Europe continues to grow steadily due to strict regulatory frameworks promoting responsible antimicrobial use, while Latin America and MEA gain momentum with improving veterinary infrastructure.

Key industry players include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco, Bayer, Ceva, and Virbac. Strategic activities in the industry include acquisitions, portfolio expansions, and regulatory approvals. Zoetis strengthened its cattle product line through the acquisition of marketing rights to Loncor 300 in February 2025. Merck Animal Health expanded its presence by acquiring Elanco's aquaculture business for USD 1.3 billion in February 2024. Boehringer Ingelheim significantly enhanced its innovation capabilities with an R&D center expansion in Georgia in November 2024. Additionally, FDA approval of Otiserene by Dechra in May 2025 introduced a novel single-dose solution for canine ear infections, contributing to expansion in the companion animal segment.

As the demand for effective veterinary therapeutics rises worldwide, companies are focusing on advanced drug delivery, regulatory compliance, and digital distribution channels. These efforts are expected to create substantial growth opportunities during the forecast period.

Buy Full Report Now: https://www.snsinsider.com/checkout/7803

FAQ

1. What is driving growth in the veterinary anti-infectives market?

Rising disease outbreaks, higher meat consumption, increased pet ownership, and advanced diagnostics are key contributors.

2. Which product type leads the market?

Antimicrobials hold the largest share due to their widespread use in livestock and companion animals.

3. Which region is growing the fastest?

Asia-Pacific shows the highest growth rate supported by expanding livestock industries and growing pet populations.

4. What challenges does the market face?

Stringent regulatory policies, lengthy approval timelines, and high development costs remain major constraints.

5. Who are the major players in the market?

Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco, Bayer, Ceva, and Virbac lead global operations.

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:

Rohan Jadhav - Principal Consultant

Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Email: info@snsinsider.com